23rd August 2021 Content supplied by: Priorclave Ltd.
New Autoclave Range from Priorclave at Lab Innovations
At this years', Lab Innovations, trade show Priorclave plan to reveal their entirely new research and laboratory-grade autoclaves.
Priorclave will continue to produce small benchtop models from 40L capacity to large 850L capacity chamber autoclaves. However, within the various new developments, each range will have more features and benefits that come as standard. This will make it easier for customers to select the best autoclave match for their specific sterilising application
Autoclave models in the new ranges will still appeal to the same diverse customer base involved in food and drink, dairy, pharmaceutical, agriculture, education, healthcare, and research establishments. And they will continue to offer a superior anti-microbial exterior finish to body panels and frames. This is a highly effective and permanent treatment for lifelong control of harmful bacteria and protects against the threat of cross-contamination. This tough special epoxy finish is proven to reduce bacterial growth by up to 99.99% and is highly effective against MRSA, E.coli, Listeria, Legionella, Campylobacter, Salmonella, Pseudomonas, and over 50 other species.
Each model will incorporate the very latest version of Tactrol®, a microprocessor controller developed by Priorclave for easy programming of the sterilising cycle.
Priorclave is renowned for the build quality, durability, and reliability of its steam sterilisers. The high standards maintained at every stage of production ensure the operational longevity of every research-grade laboratory autoclave that leaves the UK manufacturing centre. And all supported by first class before and after sales, technical support.
Priorclave can assure customers that the level of dedication applied to achieving what is considered the best autoclave build and program functionality, will be maintained through the new autoclave ranges.
Date Published: 23rd August 2021
Source article link: View
Sino Biological Announces 4.98 Billion RMB
Test Cannabis for 4 Pathogenic Aspergillus